Longeveron LGVN 深 滬
等待開盤 08-19 09:30:00 美东时间
0.809
+0.049
+6.45%
華盛通- 最 高0.8125
- 今 開0.75
- 成交量 102.81万股
- 最 低 0.725
- 昨 收 0.76
- 總市值 1214.25万
- 52周最高 2.63
- 市盈率 靜 --
- 換手率 0.01%
- 52周最低 0.633
- 委 比 20.32%
- 總股本 1500.93万
- 歷史最高 450.00
- 量 比 0.20
- 振 幅 11.51%
- 歷史最低 0.633
- 每 手 1
- 風險率 0.34%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多美股大行评级 | Macquarie维持小鹏汽车"跑赢大市"评级，目标价升至25美元
今日重点评级关注：HC Wainwright & Co.：维持BioXcel Therapeutics"买入"评级，目标价从8美元升至10美元；Craig-Hallum：维持Fennec Pharmaceuticals"买入"评级，目标价从13美元升至14美元
08-18 10:22
Roth Capital Maintains Buy on Longeveron, Lowers Price Target to $3
Roth Capital analyst Boobalan Pachaiyappan maintains Longeveron (NASDAQ:LGVN) with a Buy and lowers the price target from $10 to $3.
08-16 01:27
Longeveron shares are trading lower after the company reported worse-than-expected Q2 sales results.
Longeveron shares are trading lower after the company reported worse-than-expec...
08-15 01:28
Longeveron Q2 EPS $(0.33) Beats $(0.35) Estimate, Sales $316.000K Miss $414.650K Estimate
Longeveron (NASDAQ:LGVN) reported quarterly losses of $(0.33) per share which beat the analyst consensus estimate of $(0.35) by 5.71 percent. This is a 81.97 percent increase over losses of $(1.83) per share from the
08-14 04:40
Earnings Scheduled For August 13, 2025
Companies Reporting Before The Bell • Evotec (NASDAQ:EVO) is projected to repor...
08-13 16:32
Preview: Longeveron's Earnings
Longeveron (NASDAQ:LGVN) is set to give its latest quarterly earnings report on...
08-13 02:01
Longeveron Closes $5 Million Public Stock Offering
Longeveron ( ($LGVN) ) has issued an announcement. On August 8, 2025, Longevero...
08-12 04:52
Longeveron Announces Closing Of Up To $17.5 Million Public Offering
Longeveron Inc. (NASDAQ: LGVN) has completed a public offering, raising approximately $5.0 million upfront, with potential additional $12.5 million from short-term warrants. The funds will support clinical development of laromestrocel for treating conditions like HLHS, Alzheimer's disease, and pediatric DCM, and advancing regulatory approvals.
08-11 20:15
Longeveron® to Report Second Quarter 2025 Financial Results and Host Conference Call on August 13, 2025
Longeveron Inc. (NASDAQ: LGVN) announced it will report second quarter 2025 financial results and provide a business update on August 13, 2025, after U.S. markets close. A conference call and webcast will be held at 4:30 p.m. ET on the same day. The company specializes in regenerative medicines, with its lead product laromestrocel targeting rare pediatric and aging-related conditions.
08-05 13:15
Longeveron Licenses Issued US Patent For Stem Cell Technology From University Of Miami
Longeveron has licensed issued US Patent 12,168,028 B2, entitled "Methods for obtaining cardiomyogenic precursor cells" from the University of MiamiNew patent protects a method to derive GHRH-Receptor+ cardiomyogenic
07-21 21:16
